Sunil Agarwal, Chief Medical Officer at Ultragenyx Pharmaceutical Inc. (RARE), sold 22,500 shares at $112.73 ($2.5M) on 2015-08-20, disclosed to the SEC on 2015-08-21.
Scheduled sale ($2.5M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $116.99 | 5,480 | $641K | 25.3% |
| 2 | $107.30 | 724 | $78K | 3.1% |
| 3 | $108.98 | 1,471 | $160K | 6.3% |
| 4 | $110.40 | 4,875 | $538K | 21.2% |
| 5 | $111.21 | 2,000 | $222K | 8.8% |
| 6 | $111.90 | 930 |
| $104K |
| 4.1% |
| 7 | $112.19 | 3,370 | $378K | 14.9% |
| 8 | $112.73 | 3,650 | $411K | 16.2% |
| Total | $112.59 avg | 22,500 | $2.5M | 100% |
| Filing → |
| RARE | SELL | 2016-07-21 | $34K | — | Filing → |
| RARE | SELL | 2016-06-21 | $35K | — | Filing → |
| RARE | SELL | 2016-05-26 | $43K | — | Filing → |